迈博药业-B(02181.HK)上半年扭亏为盈至289.8万元 营收同比增长152.7%

Core Insights - The company reported a significant increase in revenue for the first half of 2025, reaching RMB 274 million, which represents a year-on-year growth of 152.7% [1] - The profit attributable to the company's owners for the same period was RMB 2.898 million, a turnaround from a loss of RMB 97.569 million in the previous year [1] - The revenue growth is primarily attributed to stable growth in pharmaceutical sales and an increase in income from exclusive promotion rights in mainland China [1]